Skip to main content
Premium Trial:

Request an Annual Quote

AnchorDx, Johnson & Johnson Collaborate on Early-Stage Lung Cancer Diagnosis Study

NEW YORK ─ AnchorDx said on Thursday that it has entered into a multi-year collaboration with the Lung Cancer Initiative at Johnson & Johnson to conduct a four-year study to enable the early detection and diagnosis of lung cancer. Specifically, the agreement is with Johnson & Johnson (China) Investment.

Investigators will enroll and track the progress of more than 3,000 patients with pulmonary nodules identified by computed tomography scanning, according to AnchorDx, a developer of next-generation sequencing-based early cancer detection and disease monitoring tests.

The study will involve collecting and analyzing clinical, imaging, and pathological data, as well as biospecimens, the firm said.

The collaborators aim to develop lung cancer molecular diagnostic tests using molecular, clinical, and imaging-based artificial intelligence technologies, Zhong Nanshan, a professor at Guangzhou Medical University who is leading the study, said in a statement.

Financial and other terms of the collaboration were not disclosed.

Guangzhou, China-based AnchorDx has developed a cell-free DNA methylation test to distinguish benign from malignant pulmonary nodules in blood and has initiated large clinical validation studies for the assay. The largest study kicked off in 2018 and seeks to enroll more than 10,000 patients across 23 hospitals in China.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.